RT Journal Article
SR Electronic
T1 A how-to-guide to building a robust SARS-CoV-2 testing program at a university-based health system
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.03.20120832
DO 10.1101/2020.06.03.20120832
A1 Stephen D. Nimer
A1 Jennifer Chapman
A1 Lisa Reidy
A1 Alvaro Alencar
A1 Yanyun Wu
A1 Sion Williams
A1 Lazara Pagan
A1 Lauren Gjolaj
A1 Jessica MacIntyre
A1 Melissa Triana
A1 Barbara Vance
A1 David Andrews
A1 Yao-Shan Fan
A1 Yi Zhou
A1 Octavio Martinez
A1 Monica Garcia-Buitrago
A1 Carolyn Cray
A1 Mustafa Tekin
A1 Jacob McCauley
A1 Philip Ruiz
A1 Paola Pagan
A1 Walter Lamar
A1 Maritza Alencar
A1 Daniel Bilbao
A1 Silvia Prieto
A1 Maritza Polania
A1 Maritza Suarez
A1 Melissa Lujardo
A1 Gloria Campos
A1 Michele Morris
A1 Bhavarth Shukla
A1 Alberto Caban-Martinez
A1 Erin Kobetz
A1 Dipen Parekh
A1 Merce Jorda
YR 2020
UL http://medrxiv.org/content/early/2020/06/08/2020.06.03.20120832.abstract
AB When South Florida became a hotspot for COVID-19 disease in March 2020, we faced an urgent need to develop test capability to detect SARS-CoV-2 infection. We assembled a transdisciplinary team of knowledgeable and dedicated physicians, scientists, technologists and administrators, who rapidly built a multi-platform, PCR- and serology-based detection program, established drive-thru facilities and drafted and implemented guidelines that enabled efficient testing of our patients and employees. This process was extremely complex, due to the limited availability of needed reagents, but outreach to our research scientists and to multiple diagnostic laboratory companies and government officials enabled us to implement both FDA authorized and laboratory developed testing (LDT)-based testing protocols. We analyzed our workforce needs and created teams of appropriately skilled and certified workers, to safely process patient samples and conduct SARS-CoV-2 testing and contact tracing. We initiated smart test ordering, interfaced all testing platforms with our electronic medical record, and went from zero testing capacity, to testing hundreds of healthcare workers and patients daily, within three weeks. We believe our experience can inform the efforts of others, when faced with a crisis situation.Competing Interest StatementThe University of Miami entered into a management agreement with Lab Corp on May 3, 2020 with Lab Corp agreeing to provide management for a broad range of clinical laboratory tests conducted on UM in-patients. MM is a member of the Viracor Eurofins medical advisory board. All other authors declare no conflicts of interest.Funding StatementNo external funding was received for tis projectAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:According to The Miller School of Medicine IRB our evaluation of the serologic tests reported in this manuscript is exempt from formal IRB approval due to the anonymity of the samples tested.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data in this manuscript has not been published elsewhere. Primary data will be made available to anyone who wishes to review it.